| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10915847 | Nuclear Medicine and Biology | 2016 | 7 Pages |
Abstract
The sigma-2 receptor could serve as a suitable targeting platform for designing radiotherapeutics. 211At-MM3 showed tumor targeting properties in vitro/in vivo and favorable estimated human dosimetry establishing the proof of concept for future development as a radiotherapeutic for the treatment of breast cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Mehran Makvandi, Brian P. Lieberman, Ben LeGeyt, Catherine Hou, David A. Mankoff, Robert H. Mach, Daniel A. Pryma,